×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HROW – harrow, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HROW
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/27
04:23 pm
hrow
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results [Yahoo! Finance]
High
Report
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results [Yahoo! Finance]
3/27
04:01 pm
hrow
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
Medium
Report
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
3/27
10:45 am
hrow
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
Low
Report
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
3/24
07:06 am
hrow
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL [Yahoo! Finance]
Medium
Report
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL [Yahoo! Finance]
3/24
07:00 am
hrow
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
Medium
Report
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
3/19
05:20 pm
hrow
Harrow: A Name I Am Accumulating [Seeking Alpha]
Low
Report
Harrow: A Name I Am Accumulating [Seeking Alpha]
3/18
01:23 pm
hrow
Harrow, Inc. (NASDAQ: HROW) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Low
Report
Harrow, Inc. (NASDAQ: HROW) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
3/17
04:01 pm
hrow
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
High
Report
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/27
04:06 pm
hrow
Form 10-K HARROW, INC. For: Dec 31
High
Report
Form 10-K HARROW, INC. For: Dec 31
3/27
04:02 pm
hrow
Form 8-K HARROW, INC. For: Mar 27
Medium
Report
Form 8-K HARROW, INC. For: Mar 27
3/26
04:05 pm
hrow
Form 4 HARROW, INC. For: Mar 24 Filed by: Opaleye Management Inc.
Low
Report
Form 4 HARROW, INC. For: Mar 24 Filed by: Opaleye Management Inc.
3/20
04:05 pm
hrow
Form 4 HARROW, INC. For: Mar 18 Filed by: Opaleye Management Inc.
Low
Report
Form 4 HARROW, INC. For: Mar 18 Filed by: Opaleye Management Inc.
3/17
05:12 pm
hrow
Form NT 10-K HARROW, INC. For: Dec 31
Low
Report
Form NT 10-K HARROW, INC. For: Dec 31
3/17
04:29 pm
hrow
Form 8-K HARROW, INC. For: Mar 17
Low
Report
Form 8-K HARROW, INC. For: Mar 17
3/4
04:44 pm
hrow
Form 4 HARROW, INC. For: Feb 28 Filed by: Opaleye Management Inc.
Medium
Report
Form 4 HARROW, INC. For: Feb 28 Filed by: Opaleye Management Inc.
1/24
09:30 pm
hrow
Form 4 HARROW, INC. For: Jan 22 Filed by: Opaleye Management Inc.
Medium
Report
Form 4 HARROW, INC. For: Jan 22 Filed by: Opaleye Management Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/13
Q3/2019 9/30/2019 EPS -0.450 ZacksConsensus -0.020 ActVsEst (0.430) - Miss
23.5%
3/13 Harrow Health Publishes Fourth Quarter 2019 Letter to Stockholders 17.2%
3/24 ImprimisRx® Announces Exclusive Agreement with Doxy.me to Provide Healthcare Professionals with Telemedicine Services 9.7%
8/15 SHAREHOLDER ALERT: Investigation of Harrow Health Announced by Holzer & Holzer, LLC 8.8%
5/9 Harrow Health Announces First Quarter 2019 Financial Results 8.2%
5/15 Harrow Health (NASDAQ: HROW) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.9%
9/5 Form 8-K HARROW HEALTH, INC. For: Sep 05 7.1%
5/12 Harrow Health, Inc. (HROW) CEO Mark Baum on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
6/25 Harrow Health Adds Two Senior Executives to its Nashville Team 5.2%
3/3 ImprimisRx® Announces Supply Agreement with Vision Center Network of America (VCNA) 4.1%
3/13 Harrow Health Publishes Fourth Quarter 2019 Letter to Stockholders 17.2%
3/24 ImprimisRx® Announces Exclusive Agreement with Doxy.me to Provide Healthcare Professionals with Telemedicine Services 9.7%
8/15 SHAREHOLDER ALERT: Investigation of Harrow Health Announced by Holzer & Holzer, LLC 8.8%
5/9 Harrow Health Announces First Quarter 2019 Financial Results 8.2%
5/15 Harrow Health (NASDAQ: HROW) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 7.9%
9/5 Form 8-K HARROW HEALTH, INC. For: Sep 05 7.1%
5/12 Harrow Health, Inc. (HROW) CEO Mark Baum on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
6/25 Harrow Health Adds Two Senior Executives to its Nashville Team 5.2%
3/3 ImprimisRx® Announces Supply Agreement with Vision Center Network of America (VCNA) 4.1%
TOP News Decliners
8/14
Form 4 HARROW HEALTH, INC. For: Aug 12 Filed by: Kammer Robert J
-24.8%
3/16 Harrow Health (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $12.75 to $12.00. They now have a "buy" rating on the stock. -24.3%
3/12 ImprimisRx® Announces Supply Agreement with EyeCare Services Partners -15.0%
5/17 Form 8-K HARROW HEALTH, INC. For: May 16 -9.3%
6/28 Form 4 HARROW HEALTH, INC. For: Jun 26 Filed by: AUSTIN STEPHEN G -8.6%
8/30 Form 8-K HARROW HEALTH, INC. For: Aug 27 -7.5%
12/11 Form 8-K HARROW HEALTH, INC. For: Dec 11 -5.7%
12/4 Harrow Health (NASDAQ: HROW) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -5.2%
4/24 Form DEF 14A HARROW HEALTH, INC. For: Apr 24 -4.8%
3/9 ImprimisRx® Announces Supply Agreement with iOR Partners -4.7%
3/16 Harrow Health (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $12.75 to $12.00. They now have a "buy" rating on the stock. -24.3%
3/12 ImprimisRx® Announces Supply Agreement with EyeCare Services Partners -15.0%
5/17 Form 8-K HARROW HEALTH, INC. For: May 16 -9.3%
6/28 Form 4 HARROW HEALTH, INC. For: Jun 26 Filed by: AUSTIN STEPHEN G -8.6%
8/30 Form 8-K HARROW HEALTH, INC. For: Aug 27 -7.5%
12/11 Form 8-K HARROW HEALTH, INC. For: Dec 11 -5.7%
12/4 Harrow Health (NASDAQ: HROW) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -5.2%
4/24 Form DEF 14A HARROW HEALTH, INC. For: Apr 24 -4.8%
3/9 ImprimisRx® Announces Supply Agreement with iOR Partners -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: